NEW YORK--(BUSINESS WIRE)--OMRIX Biopharmaceuticals, Inc. (“OMRIX” or the “Company”) (NASDAQ: OMRI), a commercial-stage biopharmaceutical company that develops and markets biosurgical and antibody-based products, announced today that it has submitted a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for approval to market Thrombin as a stand-alone product with a general hemostasis indication in surgery.
